Mainz Biomed N.V. - Ordinary Shares (QUCY)
Investment Snapshot
- P/B of 14.38 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -2,526.6%
- Revenue declining 40% annually
Mainz Biomed N.V. - Ordinary Shares (QUCY) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $9 million . Key value metrics: P/B ratio 14.38, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Mainz Biomed N.V. - Ordinary Shares — Fundamental Analysis Summary
On financial health, QUCY shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -2,526.6%, and manageable leverage with a debt-to-equity ratio of 0.31.
StockPik's composite Value Score for QUCY is 22/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
QUCY reports a high gross margin of 72.6% and a negative operating margin of -3,005.0%.
QUCY shows revenue declining at 40% year-over-year, with earnings growing at 25%.